Berten Ceulemans
Overview
Explore the profile of Berten Ceulemans including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
2725
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Wachter M, Millevert C, Nicolai J, Cats E, Kluger G, Milh M, et al.
Epilepsia
. 2025 Feb;
PMID: 39962862
Objective: Heterozygous gain-of-function (GOF) variants in KCNQ2 and KCNQ3, encoding the voltage-gated potassium channel subunits Kv7.2 and Kv7.3, lead to neurodevelopmental disorders for which no established treatments are available. Amitriptyline,...
2.
Thys L, Beysen D, Ceulemans B, Kenis S, Dielman C, Roelens F, et al.
Pediatr Neurol
. 2024 Aug;
161:1-8.
PMID: 39213953
Background: Cerebral palsy (CP) is the most frequent cause of motor impairment in children. Although perinatal asphyxia was long considered to be the leading cause of CP, recent studies demonstrate...
3.
Gil-Nagel A, Cross J, Devinsky O, Ceulemans B, Lagae L, Knupp K, et al.
Epilepsia
. 2024 Jul;
65(8):2186-2199.
PMID: 39030735
Developmental and epileptic encephalopathies (DEEs) are characterized by pharmacoresistant seizures and developmental delay. Patients with DEEs experience multiple seizure types, including tonic-clonic seizures (TCS) that can be generalized tonic-clonic (GTCS)...
4.
Smal N, Majdoub F, Janssens K, Reyniers E, Meuwissen M, Ceulemans B, et al.
Eur J Hum Genet
. 2024 Jul;
32(11):1378-1386.
PMID: 38965372
This study aimed to uncover novel genes associated with neurodevelopmental disorders (NDD) by leveraging recent large-scale de novo burden analysis studies to enhance a virtual gene panel used in a...
5.
Gallagher D, Perez-Palma E, Bruenger T, Ghanty I, Brilstra E, Ceulemans B, et al.
Epilepsia
. 2024 Feb;
65(4):1046-1059.
PMID: 38410936
Objective: SCN1A variants are associated with epilepsy syndromes ranging from mild genetic epilepsy with febrile seizures plus (GEFS+) to severe Dravet syndrome (DS). Many variants are de novo, making early...
6.
De Wachter M, Schoonjans A, Weckhuysen S, Van Schil K, Lofgren A, Meuwissen M, et al.
Eur J Paediatr Neurol
. 2023 Dec;
48:46-60.
PMID: 38039826
The implementation of whole exome sequencing (WES) has had a major impact on the diagnostic yield of genetic testing in individuals with epilepsy. The identification of a genetic etiology paves...
7.
Romaen K, Van Ussel I, Van Rossem C, Kenis S, Ceulemans B, Van Hoorenbeeck K, et al.
Front Pediatr
. 2023 Nov;
11:1267345.
PMID: 38027271
Introduction: Children with cerebral palsy (CP) often present with chronic respiratory symptoms. (PA), is a known pathogen associated with more severe respiratory disease. Preventive actions to eradicate this bacterium and...
8.
Musto E, Liao V, Johannesen K, Fenger C, Lederer D, Kothur K, et al.
Ann Neurol
. 2023 Aug;
PMID: 37606373
Objective: Variants in GABRA1 have been associated with a broad epilepsy spectrum, ranging from genetic generalized epilepsies to developmental and epileptic encephalopathies. However, our understanding of what determines the phenotype...
9.
Sullivan J, Lagae L, Cross J, Devinsky O, Guerrini R, Knupp K, et al.
Epilepsia
. 2023 Aug;
64(10):2653-2666.
PMID: 37543865
Objective: This study was undertaken to assess the safety and efficacy of fenfluramine in the treatment of convulsive seizures in patients with Dravet syndrome. Methods: This multicenter, randomized, double-blind, placebo-controlled,...
10.
Verheyen K, Wyers L, Lambrecht E, Schoonjans A, Ceulemans B, Van de Walle P, et al.
Dev Med Child Neurol
. 2023 Feb;
65(10):1343-1356.
PMID: 36852703
Aim: This cohort study aimed to describe functional mobility in Dravet syndrome, a developmental and epileptic encephalopathy. Method: Functional mobility was assessed in individuals (aged 3-25 years), diagnosed with Dravet...